肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CHMP对伊布替尼在欧洲两种适应症扩大持积极态度

2019-06-29 Allan MedSci原创

伊布替尼CHMP适应症扩大
关注

强生公司近日宣布，欧洲药品管理局（EMA）的人用药品委员会（CHMP）建议扩大伊布替尼的适应症：一项是建议将伊布替尼与obinutuzumab联合用于治疗初治慢性淋巴细胞白血病（CLL）的成人患者；另外一项是建议将伊布替尼与利妥昔单抗联合用于治疗华氏巨球蛋白血症（WM）的成人患者。

强生公司近日宣布，欧洲药品管理局（EMA）的人用药品委员会（CHMP）建议扩大伊布替尼的适应症：一项是建议将伊布替尼与obinutuzumab联合用于治疗初治慢性淋巴细胞白血病（CLL）的成人患者；另外一项是建议将伊布替尼与利妥昔单抗联合用于治疗华氏巨球蛋白血症（WM）的成人患者。

iNNOVATE和iLLUMINATE研究的最新数据支持了伊布替尼联合用药在治疗CLL和WM患者中的有效性。iNNOVATE和iLLUMINATE研究的研究人员说：“伊布替尼在CLL和WM中的最新联合方案显示出伊布替尼进一步延长患者生存期的潜力”。


原始出处：

http://www.firstwordpharma.com/node/1650391

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1288773, encodeId=405c1288e7383, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25659, encryptionId=11fd2565952, topicName=伊布替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302666, encodeId=976b13026660d, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336782, encodeId=a27b1336e823d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339201, encodeId=e77c133920155, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 hongbochen

    #伊布替尼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1288773, encodeId=405c1288e7383, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25659, encryptionId=11fd2565952, topicName=伊布替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302666, encodeId=976b13026660d, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336782, encodeId=a27b1336e823d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339201, encodeId=e77c133920155, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 医生2394

    #CHMP#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1288773, encodeId=405c1288e7383, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25659, encryptionId=11fd2565952, topicName=伊布替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302666, encodeId=976b13026660d, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336782, encodeId=a27b1336e823d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339201, encodeId=e77c133920155, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 644982816_68283321

    #适应症#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1288773, encodeId=405c1288e7383, content=<a href='/topic/show?id=11fd2565952' target=_blank style='color:#2F92EE;'>#伊布替尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=25659, encryptionId=11fd2565952, topicName=伊布替尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1302666, encodeId=976b13026660d, content=<a href='/topic/show?id=1b6846653e' target=_blank style='color:#2F92EE;'>#CHMP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4665, encryptionId=1b6846653e, topicName=CHMP)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b505306, createdName=医生2394, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1336782, encodeId=a27b1336e823d, content=<a href='/topic/show?id=554d94e13ae' target=_blank style='color:#2F92EE;'>#适应症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94713, encryptionId=554d94e13ae, topicName=适应症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3dd32500118, createdName=644982816_68283321, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339201, encodeId=e77c133920155, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/PiajxSqBRaEKxsKDoOOFxGpMibw6lsQFUIicWt7kWGevkdgFhjiban1icD2JdIBmjVo7qX7aSlCSpiaia382nuLKiaI3Cg/132, createdBy=5c442500150, createdName=ms9474365431325850, createdTime=Mon Jul 01 02:50:00 CST 2019, time=2019-07-01, status=1, ipAttribution=)]
    2019-07-01 ms9474365431325850

    #欧洲#

    0

相关资讯

2018年IWWM 会议现场直达：伊布替尼治疗华氏巨球蛋白血症突破性进展！

前言第十届华氏巨球蛋白血症国际研讨会（International Workshop on Waldenström’s Macroglobulinemia，IWWM）已于2018年10月11日至13日在美国纽约召开。2018年IWWM会议可谓是一场基因研究与治疗进展的盛宴，汇聚了华氏巨球蛋白血症（WM）领域的最前沿信息。众多与会研究既有WM基因组学信息，如MYD88、CXCR4、Del(6q)、

强生公司寻求在欧洲扩大伊布替尼的适应症

强生公司近日宣布，已向欧洲药品管理局（EMA）提交了两份申请，以寻求扩大伊布替尼的适应症。第一项申请旨在申请在先前未治疗的成人慢性淋巴细胞白血病（CLL）中使用伊布替尼与obinutuzumab的组合，第二项申请旨在申请在先前未治疗和复发/难治的华氏巨球蛋白血症（WM）中使用伊布替尼与利妥昔单抗的组合。

2018 CSH：马军教授：伊布替尼进医保，高效安全可负担，更多淋巴瘤患者进入无化疗时代！

中华医学会第十五次全国血液学学术会议在成都盛大开幕。以伊布替尼为代表的新型选择性BTK靶向口服药物成为血液肿瘤领域的一大热点。特邀哈尔滨血液病肿瘤研究所的马军教授，详细解读了伊布替尼RESONATE-2研究以及伊布替尼进国家医保所带来的现实意义。

FDA批准：AbbVie与强生公司的伊布替尼作为CLL一线治疗的第一个非化疗联合方案

AbbVie和强生公司周一（2019年1月28号）宣布，FDA已经批准Imbruvica（伊布替尼）与Roche的Gazyva（obinutuzumab）联合用于治疗初治慢性淋巴细胞白血病/小淋巴细胞淋巴瘤（CLL / SLL）患者。两家公司指出，这是CLL / SLL的非化疗联合方案的首次授权。

CSH重磅发布：伊布替尼一线治疗CLL研究RESONATE-2发布55个月随访结果

RESONATE-2是当前唯一一项具有长期随访数据的全球、多中心、大规模、III期BTK抑制剂治疗CLL/SLL的随机对照研究，旨在探讨伊布替尼一线治疗CLL/SLL的疗效与安全性。该研究的随访结果持续在ASH、EHA等重要学术会上公布，备受临床专家关注。2018年10月25-28日，中华医学会第15次全国血液学学术会议期间，美国MD Anderson的Jan A. Burger教授公布了RESO

NEJM：伊布替尼用于老年慢性淋巴细胞白血病

研究认为，伊布替尼疗法对老年慢性淋巴细胞白血病患者的疗效显著优于传统化疗